vs
Side-by-side financial comparison of Microchip Technology (MCHP) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Microchip Technology is the larger business by last-quarter revenue ($1.2B vs $622.0M, roughly 1.9× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 5.3%, a 29.2% gap on every dollar of revenue. On growth, Microchip Technology posted the faster year-over-year revenue change (15.6% vs 4.8%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs -5.4%).
Microchip Technology Incorporated is an American publicly traded semiconductor corporation that manufactures microcontroller, mixed-signal, analog, and Flash-IP integrated circuits.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
MCHP vs RPRX — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $622.0M |
| Net Profit | $62.7M | $214.2M |
| Gross Margin | 59.6% | — |
| Operating Margin | 12.8% | 62.4% |
| Net Margin | 5.3% | 34.4% |
| Revenue YoY | 15.6% | 4.8% |
| Net Profit YoY | 217.0% | 2.9% |
| EPS (diluted) | $0.06 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $622.0M | ||
| Q3 25 | $1.1B | $609.3M | ||
| Q2 25 | $1.1B | $578.7M | ||
| Q1 25 | $970.5M | $568.2M | ||
| Q4 24 | $1.0B | $593.6M | ||
| Q3 24 | $1.2B | $564.7M | ||
| Q2 24 | $1.2B | $537.3M | ||
| Q1 24 | $1.3B | $568.0M |
| Q4 25 | $62.7M | $214.2M | ||
| Q3 25 | $41.7M | $288.2M | ||
| Q2 25 | $-18.6M | $30.2M | ||
| Q1 25 | $-154.6M | $238.3M | ||
| Q4 24 | $-53.6M | $208.2M | ||
| Q3 24 | $78.4M | $544.0M | ||
| Q2 24 | $129.3M | $102.0M | ||
| Q1 24 | $154.7M | $4.8M |
| Q4 25 | 59.6% | — | ||
| Q3 25 | 55.9% | — | ||
| Q2 25 | 53.6% | — | ||
| Q1 25 | 51.6% | — | ||
| Q4 24 | 54.7% | — | ||
| Q3 24 | 57.4% | — | ||
| Q2 24 | 59.4% | — | ||
| Q1 24 | 59.6% | — |
| Q4 25 | 12.8% | 62.4% | ||
| Q3 25 | 7.8% | 70.1% | ||
| Q2 25 | 3.0% | 36.3% | ||
| Q1 25 | -10.3% | 94.0% | ||
| Q4 24 | 3.0% | 60.9% | ||
| Q3 24 | 12.6% | — | ||
| Q2 24 | 17.7% | 50.2% | ||
| Q1 24 | 19.1% | -13.0% |
| Q4 25 | 5.3% | 34.4% | ||
| Q3 25 | 3.7% | 47.3% | ||
| Q2 25 | -1.7% | 5.2% | ||
| Q1 25 | -15.9% | 41.9% | ||
| Q4 24 | -5.2% | 35.1% | ||
| Q3 24 | 6.7% | 96.3% | ||
| Q2 24 | 10.4% | 19.0% | ||
| Q1 24 | 11.7% | 0.8% |
| Q4 25 | $0.06 | $0.49 | ||
| Q3 25 | $0.03 | $0.67 | ||
| Q2 25 | $-0.09 | $0.07 | ||
| Q1 25 | $-0.29 | $0.55 | ||
| Q4 24 | $-0.10 | $0.46 | ||
| Q3 24 | $0.14 | $1.21 | ||
| Q2 24 | $0.24 | $0.23 | ||
| Q1 24 | $0.29 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $250.7M | $618.7M |
| Total DebtLower is stronger | $5.4B | $9.0B |
| Stockholders' EquityBook value | $6.6B | $9.7B |
| Total Assets | $14.3B | $19.6B |
| Debt / EquityLower = less leverage | 0.82× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $250.7M | $618.7M | ||
| Q3 25 | $236.8M | $938.9M | ||
| Q2 25 | $566.5M | $631.9M | ||
| Q1 25 | $771.7M | $1.1B | ||
| Q4 24 | $586.0M | $929.0M | ||
| Q3 24 | $286.1M | $950.1M | ||
| Q2 24 | $315.1M | $1.8B | ||
| Q1 24 | $319.7M | $843.0M |
| Q4 25 | $5.4B | $9.0B | ||
| Q3 25 | $5.4B | $8.9B | ||
| Q2 25 | $5.5B | $8.0B | ||
| Q1 25 | $5.6B | $7.6B | ||
| Q4 24 | $6.7B | $7.6B | ||
| Q3 24 | $6.4B | $7.6B | ||
| Q2 24 | $6.2B | $7.6B | ||
| Q1 24 | $6.0B | $6.1B |
| Q4 25 | $6.6B | $9.7B | ||
| Q3 25 | $6.7B | $9.6B | ||
| Q2 25 | $6.9B | $9.5B | ||
| Q1 25 | $7.1B | $9.8B | ||
| Q4 24 | $6.0B | $10.3B | ||
| Q3 24 | $6.3B | $10.3B | ||
| Q2 24 | $6.4B | $9.8B | ||
| Q1 24 | $6.7B | $9.9B |
| Q4 25 | $14.3B | $19.6B | ||
| Q3 25 | $14.5B | $19.3B | ||
| Q2 25 | $15.0B | $18.3B | ||
| Q1 25 | $15.4B | $17.6B | ||
| Q4 24 | $15.6B | $18.2B | ||
| Q3 24 | $15.6B | $18.0B | ||
| Q2 24 | $15.8B | $17.7B | ||
| Q1 24 | $15.9B | $16.1B |
| Q4 25 | 0.82× | 0.92× | ||
| Q3 25 | 0.80× | 0.93× | ||
| Q2 25 | 0.80× | 0.84× | ||
| Q1 25 | 0.80× | 0.78× | ||
| Q4 24 | 1.12× | 0.74× | ||
| Q3 24 | 1.02× | 0.74× | ||
| Q2 24 | 0.96× | 0.78× | ||
| Q1 24 | 0.90× | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $341.4M | $827.1M |
| Free Cash FlowOCF − Capex | $318.9M | — |
| FCF MarginFCF / Revenue | 26.9% | — |
| Capex IntensityCapex / Revenue | 1.9% | — |
| Cash ConversionOCF / Net Profit | 5.44× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | $819.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $341.4M | $827.1M | ||
| Q3 25 | $88.1M | $702.6M | ||
| Q2 25 | $275.6M | $364.0M | ||
| Q1 25 | $205.9M | $596.1M | ||
| Q4 24 | $271.5M | $742.5M | ||
| Q3 24 | $43.6M | $703.6M | ||
| Q2 24 | $377.1M | $658.2M | ||
| Q1 24 | $430.0M | $664.6M |
| Q4 25 | $318.9M | — | ||
| Q3 25 | $51.6M | — | ||
| Q2 25 | $257.7M | — | ||
| Q1 25 | $191.7M | — | ||
| Q4 24 | $253.4M | — | ||
| Q3 24 | $22.8M | — | ||
| Q2 24 | $304.2M | — | ||
| Q1 24 | $389.9M | — |
| Q4 25 | 26.9% | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 24.0% | — | ||
| Q1 25 | 19.8% | — | ||
| Q4 24 | 24.7% | — | ||
| Q3 24 | 2.0% | — | ||
| Q2 24 | 24.5% | — | ||
| Q1 24 | 29.4% | — |
| Q4 25 | 1.9% | — | ||
| Q3 25 | 3.2% | — | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.8% | — | ||
| Q3 24 | 1.8% | — | ||
| Q2 24 | 5.9% | — | ||
| Q1 24 | 3.0% | — |
| Q4 25 | 5.44× | 3.86× | ||
| Q3 25 | 2.11× | 2.44× | ||
| Q2 25 | — | 12.06× | ||
| Q1 25 | — | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | 0.56× | 1.29× | ||
| Q2 24 | 2.92× | 6.45× | ||
| Q1 24 | 2.78× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MCHP
| Mixed Signal Microcontrollers | $586.5M | 49% |
| Analog | $322.9M | 27% |
| Other Product Line | $276.6M | 23% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
